Periconceptional intake of vitamin supplements and risk of multiple congenital anomalies.
Numerous studies have reported reduced risks for a variety of single congenital anomaly phenotypes associated with maternal periconceptional use of vitamin supplements containing folic acid. Here we investigated whether periconceptional use of vitamin supplements containing folic acid by women altered their risk for delivering infants with multiple congenital anomalies (MCAs). Data were derived from a case-control study representing deliveries (fetal deaths and infants) from 2 California counties between January 1993 and July 1996. MCAs were defined as 2 or more congenital anomalies affecting more than one organ system or a major anomaly in combination with 2 minor anomalies. Controls were randomly selected from nonmalformed live-born infants. Telephone interviews were conducted with 112 (73.7% of eligible) case and 195 (78.0% of eligible) control mothers. Compared to women who did not use multivitamin supplements containing folic acid in the period 3 months before through 3 months after conception, women who used in this time period were observed to have an elevated risk to deliver fetuses or infants with MCAs, odds ratio = 2.6 (95% confidence interval 1.1-6.2). This elevated risk was not substantially altered (adjusted odds ratio = 2.9 [0.8-10.3]) by adjusting for maternal race/ethnicity, education, gravidity, body mass index, alcohol consumption, and cigarette smoking. No particular organ system seemed to be uniquely represented among the MCA fetuses and infants whose mothers used vitamin supplements. The observed elevated risk associated with maternal vitamin use is considered to be preliminary and needs to be replicated in other populations.
California Birth Defects Monitoring Program, Emeryville 94608, USA.
G M
GM
Shaw
L A
LA
Croen
K
K
Todoroff
M M
MM
Tolarova
D000015:Abnormalities, Multiple / Q000235:genetics* / Q000517:prevention & control*; D016022:Case-Control Studies; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016017:Odds Ratio; D010641:Phenotype; D016742:Preconception Care; D011247:Pregnancy; D012307:Risk Factors; D014815:Vitamins / Q000627:therapeutic use*
D014815:Vitamins; D005492:Folic Acid